Latest Conference Articles

August 7th 2022, 4:42pm

IASLC World Conference on Lung Cancer

David S. Hong, MD, discusses the significance of larotrectinib in the treatment of non–small cell lung cancer and other solid tumors harboring NTRK gene fusions.

August 7th 2022, 4:40pm

IASLC World Conference on Lung Cancer

Wade T. Iams, MD, discusses the evaluation of sotorasib in KRAS G12C–mutant solid tumors, including non–small cell lung cancer.

August 7th 2022, 3:55pm

IASLC World Conference on Lung Cancer

A lead-in dosing strategy for the combination of sotorasib in combination with either pembrolizumab or atezolizumab showed promising efficacy and relatively low rates of hepatotoxicity in patients with KRAS G12C–positive non–small cell lung cancer.

August 7th 2022, 3:33pm

IASLC World Conference on Lung Cancer

Sitravatinib in combination with tislelizumab demonstrated a confirmed investigator-assessed overall response rate of 30.4% in patients with PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.

August 7th 2022, 3:05pm

IASLC World Conference on Lung Cancer

GDC-6036, a novel KRAS G12C inhibitor, produced encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated NSCLC, according to data from a phase 1a trial.

August 7th 2022, 2:33pm

IASLC World Conference on Lung Cancer

Sintilimab, both as a single agent and in combination with chemotherapy, generated comparable efficacy and safety vs pembrolizumab in patients with untreated metastatic non–small cell lung cancer.

August 7th 2022, 1:30pm

IASLC World Conference on Lung Cancer

Four distinct subgroups, each associated with distinctive signaling pathways, microenvironments, and clinical-pathologic futures, were discovered in a population of patients with MET exon 14 skipping non–small cell lung cancer.

August 7th 2022, 11:21am

IASLC World Conference on Lung Cancer

Sugemalimab appeared to be safe and effective when used as consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) who did not have disease progression following concurrent chemoradiation or sequential chemoradiation.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

The combination use of first-line durvalumab plus tremelimumab for the treatment of patients with metastatic non–small cell lung cancer improved overall survival compared with standard-of-care chemotherapy.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Larotrectinib continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial and phase 1 LOXO-TRK-14001 trial.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Ociperlimab, an anti-TIGIT monoclonal antibody, plus the anti–PD-L1 monoclonal antibody tislelizumab induced promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non­–small cell lung cancer, according to data from the dose-expansion cohort of the AdvanTIG-105 trial.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

The addition of tremelimumab to durvalumab and chemotherapy improved clinical benefit and survival benefit vs. chemotherapy alone in patients with PD-L1–negative metastatic non–small cell lung cancer.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Second- or third-line tislelizumab continued to display an overall survival benefit vs docetaxel in patients with non–small cell lung cancer.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Investigators are evaluating the combination of repotrectinib and osimertinib for the treatment of patients with advanced or metastatic EGFR-mutant non–small cell lung cancer in the phase 1 TOTEM trial.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

The antibody-drug conjugate sacituzumab govitecan will be evaluated vs single-agent docetaxel during the phase 3 EVOKE-01 trial in patients with metastatic non–small cell lung cancer.

August 5th 2022, 7:41pm

IASLC World Conference on Lung Cancer

Acquired resistance because of genetic alterations in the MET receptor has limited the efficacy of the EGFR inhibitor osimertinib in patients with non–small cell lung cancer. Investigators have sought to circumvent this barrier through targeting MET protein activity with the addition of the novel MET TKI, savolitinib.

August 2nd 2022, 9:50pm

IASLC World Conference on Lung Cancer

Eftilagimod alpha plus pembrolizumab demonstrated promising benefits in overall survival and progression-free survival as a second-line treatment in patients with non–small cell lung cancer who progressed on anti–PD-1/anti–PD-L1 therapy.

July 30th 2022, 8:42pm

International Congress on the Future of Breast Cancer West

As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.

July 30th 2022, 8:04pm

International Congress on the Future of Breast Cancer West

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.